Cardiovascular
Read More about this categoryShow Less
Cardiovascular
The cardiovascular system consists of the heart, blood and blood vessels. These organs form the 3 major closed circulation systems in the body, i.e., the pulmonary, coronary and systemic circulations. Cardiovascular disease includes heart disease, vascular diseases of the brain and kidney, and peripheral arterial diseases. Cardiovascular disease is the leading cause of death globally. Studies on cardiovascular regulation are important to provide a better understanding of this group of diseases and to help improve the corresponding treatment.
Research Areas
- Acute Phase Reactants(15)
- Angina(14)
- Arrhythmia(82)
- Atherosclerosis(88)
- Chronic Kidney Disease(18)
- Coagulation & Hemostasis(124)
- Coronary Artery Disease(7)
- Diabetic Nephropathy(8)
- Endothelium(33)
- Erythrocytes & Hemoglobin(49)
- Heart Failure(33)
- Hypertension(162)
- Hypotension(24)
- Lipoproteins(61)
- Myocardial Contractility(33)
- Myocardial Hypertrophy(21)
- Myocardial Infarction(61)
- Others(1)
- Serum Proteins(11)
- Smooth Muscle Cells(36)
- Storage & Transport(6)
- Stroke(48)
- Thrombosis(52)
- Vasoconstriction(59)
- Vasodilation(141)
- Cardiomyopathy(5)
- Cholesterol Metabolism(44)
Products Related to Cardiovascular(821)
- GC49690(3R,5R)-Rosuvastatin (calcium salt)CAS: 1422515-55-6Purity: >95.00%
ロスバスタチンの大量製剤に見つかる可能性のある不純物
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC49682 | Dabigatran-d3 | 1246817-44-6 | >99.00% | |
ダビガトランの定量化のための内部標準物質 | ||||
| GC49683 | N-desethyl-N-methyl Vardenafil | 224785-87-9 | >95.00% | |
商業的なバルデナフィル製剤に見つかる可能性のある不純物 | ||||
| GC49684 | Dabigatran-13C-d3 | 2967480-55-1 | >99.00% | |
ダビガトランの定量化のための内部標準物質 | ||||
| GC49690 | (3R,5R)-Rosuvastatin (calcium salt) | 1422515-55-6 | >95.00% | |
ロスバスタチンの大量製剤に見つかる可能性のある不純物 | ||||
| GC49706 | Cerberin | 25633-33-4 | >98.00% | |
細胞毒性と心臓調節作用を持つカルジャックスシド。 | ||||
| GC49733 | 1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PC | 99264-98-9 | >95.00% | |
リン脂質 | ||||
| GC49738 | Lipid 29 | 2244716-55-8 | >98.00% | |
イオン化可能なアミノ脂質 | ||||
| GC49762 | Etiocholanedione | 1229-12-5 | >98.00% | |
神経ステロイド | ||||
| GC49770 | Stearic Acid glycidyl ester-d5 | 1346598-19-3 | >99.00% | |
ステアリン酸グリシジルエステルの定量化のための内部標準 | ||||
| GC49777 | Valsartan Acid | 164265-78-5 | >95.00% | |
バルサルタンの変換物質 | ||||
| GC49784 | AZD 2716 | 1845753-81-2 | >98.00% | |
sPLA 2 阻害剤 | ||||
| GC49812 | Urobilin (hydrochloride) | 28925-89-5 | - | |
ヘモグロビン分解の副産物 | ||||
| GC49836 | Benoxaprofen | 51234-28-7 | >98.00% | |
ベノキサプロフェン (LRCL 3794) は、強力で長時間作用する抗炎症および解熱化合物です。 | ||||
| GC49842 | Digoxigenin Bisdigitoxoside | 5297-05-2 | >98.00% | |
Na+/K+-ATPase阻害剤 | ||||
| GC49863 | Cytarabine 5′-monophosphate | 7075-11-8 | >95.00% | |
シタラビンの活性代謝物質 | ||||
| GC49866 | Desmethyl Carvedilol | 72956-44-6 | >90.00% | |
カルビドロールの活性代謝物 | ||||
| GC49873 | Protectin D1 methyl ester | 934005-36-4 | >95.00% | |
プロテクチンD1のエステル化形 | ||||
| GC49880 | Bradykinin (trifluoroacetate salt) | - | >95.00% | |
内因性血管拡張剤 | ||||
| GC49882 | Hemokinin 1 (human) (trifluoroacetate salt) | - | >98.00% | |
NK 1 受容体のペプチドアゴニスト | ||||
| GC49884 | Trigonelline-d3 (chloride) | - | >99.00% | |
トリゴネリンの定量化のための内部標準 | ||||
| GC49885 | BQ-3020 (trifluoroacetate salt) | - | >90.00% | |
ペプチドETB受容体拮抗剤 | ||||
| GC49890 | β-Glycerophosphate-d5 (sodium salt hydrate) | - | >99.00% | |
β-グリセロホスファートの定量化のための内部標準 | ||||
| GC49916 | Lys-(Des-Arg9, Leu8)-Bradykinin (trifluoroacetate salt) | - | >95.00% | |
ブラジキニンB1受容体拮抗剤 | ||||
| GC50009 | LY 294002 hydrochloride | 934389-88-5 | >98.00% | |
典型的なPI 3キナーゼ阻害剤。他のキナーゼも抑制します。 | ||||